Allogene Therapeutics, Inc. · NASDAQ:ALLO
Douglas Earl Martin sold 29,697 Allogene Therapeutics, Inc. shares (Form 4)
Traded Aug 21, 2026 · Filed Aug 25, 2026
On Aug 21, 2026, Douglas Earl Martin (SVP, General Counsel) sold 29,697 Allogene Therapeutics, Inc. shares at US$2.12 for US$62,958, leaving 488,267 shares. Filed Aug 25, 2026 (Form 4).
- Sold
- 29,697 shares
- Price
- US$2.12
- Value
- US$62,958
- Holding after
- 488,267 shares
- Trading plan
- No
- Role
- SVP, General Counsel
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Common Stock | Sale | 29,697 | US$2.12 | 488,267 | Direct |
Source
Related
- Allogene Therapeutics, Inc.
- Douglas Earl Martin
- Allogene Therapeutics, Inc. shareholders
- Schedule 13D/A · Tpg Gp A, LLC · Sep 30, 2026
- Schedule 13G/A · Frazier Life Sciences Public Fund, L.P. · Aug 14, 2026
- Schedule 13G/A · Arie Belldegrun, M.D. · Aug 7, 2026
- Schedule 13G · State Street Corp · Aug 7, 2026
- Form 4 · Kazam Joshua A · Jun 23, 2026